SwitzerlandSwitzerland

Molecular Partners signs US$420 million contract on antibody mimetic with Allergan

05.05.2011

Zurich/Schlieren – Swiss Molecular Partners AG has bagged a US$45 million upfront payment and the option for additional US$345 million milestones from Allergan Inc for an exclusive licence of its Phase 2 anti-VEGF antibody mimetic MP0112 for the treatment of retinal diseases. In addition, Molecular Partners could receive tiered double-digit royalties on any future sales of MP0112. Allergan gains exclusive global rights for MP0112 for ophthalmic indications of the so-called DARPin molecule. DARPins are temperature stable, 14KDa scaffolds of 2-4 domains of the ankyrin protein motif that mimic the antigen binding capacities of antibody drugs while offering advantages of smaller molecules. Data on MP0112 from two separate phase I/IIa trials in wet age-related macular degeneration (wetAMD) and diabetic macular edema (DME) suggest that MP0112 is well-tolerated and has a potentially long lasting effect on vision gain after one single injection. In the studies, for most patients in the cohorts treated with the higher dose of the investigational compound, the potential beneficial effect on visual acuity lasted for approximately 16 weeks.

SwitzerlandSwitzerland

21.02.2012

Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...

SwitzerlandSwitzerland

26.01.2012

Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....

SwitzerlandSwitzerland

23.01.2012

Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...

SwitzerlandSwitzerland

19.12.2011

Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...

SwitzerlandSwitzerland

17.12.2011

Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...

SwitzerlandSwitzerland

14.12.2011

Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...

SwitzerlandSwitzerland

14.12.2011

Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...

SwitzerlandSwitzerland

22.11.2011

Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...

SwitzerlandSwitzerland

16.11.2011

Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/1/article/molecular-partners-signs-us420-million-contract-on-antibody-mimetic-with-allergan.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK70.9%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.1%
  • IMMUNICUM AB (S)16.60 SEK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP750.0%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-96.0%
  • EVOCUTIS (UK)0.22 GBP-92.3%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 22.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper